Unknown

Dataset Information

0

Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients.


ABSTRACT: Clinical benefits from trastuzumab and other anti-HER2 therapies in patients with HER2 amplified breast cancer remain limited by primary or acquired resistance. To identify potential mechanisms of resistance, we established trastuzumab-resistant HER2 amplified breast cancer cells by chronic exposure to trastuzumab treatment. Genomewide copy-number variation analyses of the resistant cells compared with parental cells revealed a focal amplification of genomic DNA containing the cyclin E gene. In a cohort of 34 HER2(+) patients treated with trastuzumab-based therapy, we found that cyclin E amplification/overexpression was associated with a worse clinical benefit (33.3% compared with 87.5%, P < 0.02) and a lower progression-free survival (6 mo vs. 14 mo, P < 0.002) compared with nonoverexpressing cyclin E tumors. To dissect the potential role of cyclin E in trastuzumab resistance, we studied the effects of cyclin E overexpression and cyclin E suppression. Cyclin E overexpression resulted in resistance to trastuzumab both in vitro and in vivo. Inhibition of cyclin E activity in cyclin E-amplified trastuzumab resistant clones, either by knockdown of cyclin E expression or treatment with cyclin-dependent kinase 2 (CDK2) inhibitors, led to a dramatic decrease in proliferation and enhanced apoptosis. In vivo, CDK2 inhibition significantly reduced tumor growth of trastuzumab-resistant xenografts. Our findings point to a causative role for cyclin E overexpression and the consequent increase in CDK2 activity in trastuzumab resistance and suggest that treatment with CDK2 inhibitors may be a valid strategy in patients with breast tumors with HER2 and cyclin E coamplification/overexpression.

SUBMITTER: Scaltriti M 

PROVIDER: S-EPMC3048107 | biostudies-literature | 2011 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients.

Scaltriti Maurizio M   Eichhorn Pieter J PJ   Cortés Javier J   Prudkin Ludmila L   Aura Claudia C   Jiménez José J   Chandarlapaty Sarat S   Serra Violeta V   Prat Aleix A   Ibrahim Yasir H YH   Guzmán Marta M   Gili Magui M   Rodríguez Olga O   Rodríguez Sonia S   Pérez José J   Green Simon R SR   Mai Sabine S   Rosen Neal N   Hudis Clifford C   Baselga José J  

Proceedings of the National Academy of Sciences of the United States of America 20110214 9


Clinical benefits from trastuzumab and other anti-HER2 therapies in patients with HER2 amplified breast cancer remain limited by primary or acquired resistance. To identify potential mechanisms of resistance, we established trastuzumab-resistant HER2 amplified breast cancer cells by chronic exposure to trastuzumab treatment. Genomewide copy-number variation analyses of the resistant cells compared with parental cells revealed a focal amplification of genomic DNA containing the cyclin E gene. In  ...[more]

Similar Datasets

| S-EPMC7678934 | biostudies-literature
| S-EPMC3858548 | biostudies-literature
| S-EPMC8256255 | biostudies-literature
| S-EPMC7494777 | biostudies-literature
| S-EPMC5934551 | biostudies-literature
| S-EPMC4261073 | biostudies-literature
| S-EPMC6683360 | biostudies-literature
| S-EPMC8722291 | biostudies-literature
| S-EPMC3600586 | biostudies-literature
| S-EPMC3268553 | biostudies-literature